Floatz logo

MVT-5873 (FULLY HUMAN, IGG1 ANTIBODY TARGETING SIALYL LEWIS A)

Colon Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
65/ 100

Competitive context

158 Active assets in the Colon Carcinoma cohort.

Asset / SponsorPhaseRating
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB
Eloxatin
Sun Yat-sen University
Phase 3BB
Palbociclib
Lebanese University
Phase 2BB

View all 50 →

Same molecule, other indications

MVT-5873 (FULLY HUMAN, IGG1 ANTIBODY TARGETING SIALYL LEWIS A) is also rated in:

pancreatic neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
cholangiocarcinomaDormant
CC
Indicative ·
41 / 100
View asset →
Liver MetastasisDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →